Korsana Biosciences at Stifel 2026 Healthcare Conference 2026: cash-rich push
At a glance
- $KRSA today+3.25%last $32.68
- Vs industry peers+3.65 pts6-peer median −0.39% · far ahead
- Since Nov 10+5.52%from the first trade after the story
- 52-week range354.6% above low$7.19 – $59.36
- Cash runway~6.9 yrs$456.2M cash ÷ $5.5M/mo burn · 10-Q
- Coverage11 this week20 in 30 days · 2.4× its usual pace
Nothing reported about korsana biosciences across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Policy shifts the whole aisle, but trial results shift individual stocks. Knowing which kind of story this is helps you spot the real movers.
- How the stocks are trading: $KRSA +3.25%, $SF -0.22%, $HR +0.00% in the latest session.
- Timing: It was published while New York was trading, so the day's move may already include the first reaction.
Where the stock stands
Korsana Biosciences ($KRSA) gained 3.25% to $32.68 in the latest session. Over the past month it is up 4.0%. It now sits 45% under the 52-week high of $59.36 and 355% above the year's low of $7.19. It has been a volatile year: the high was 8.3 times the low, so moves this size are not unusual for it. Stifel Financial ($SF) slipped 0.22% to $72.59 in the latest session. Over the past month it is up 9.9%. It now sits 19% under the 52-week high of $89.83 and 11% above the year's low of $65.40. The high sits 37% above the low, a moderate range for a year.
What the filings say
In its latest report (10-Q, filed Nov 5, 2026), $KRSA lost $46.4M over the quarter to Sep 30, 2026. Operations used $49.4M of cash over the nine months to Sep 30, 2026 — about $5.5M a month — against $456.2M in cash on Sep 30, 2026. At that pace the cash covers about 6.9 years. Total liabilities were $45.6M against $456.2M of cash on Sep 30, 2026. Its most recent filings before this story: 10-Q on Nov 5, 2026, 8-K on Nov 5, 2026, 8-K on Sep 11, 2026. Figures are as filed with the SEC; the $KRSA page has the full statements.
How much coverage it is getting
This is one of 20 stories on these companies in Wook's last 30 days of coverage, including 11 this week. That is running well ahead of normal: over the month it has averaged about 5 a week. Going by their wording, 25% read bullish, 75% neutral and 0% bearish. This one reads neutral, like most of them. Investing.com wrote 11 of the 20 (55%), so the count reflects one outlet's output more than broad attention.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $KRSA page, and they say what management has disclosed without a reporter in between. Most of the recent coverage comes from one outlet, so check whether another newsroom has confirmed the story or is only repeating it. Wook AI, at the top of the page, can work out how far $KRSA is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 10, 2026. $KRSA has moved +5.52% ($30.97 to $32.68), $SF has moved -1.22% ($73.49 to $72.59) and $HR has moved +0.13% ($19.30 to $19.32). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
